Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study.

Journal of global antimicrobial resistance - 1 Mar 2022

Gagliardini Roberta, Baccini Michela, Modica Sara, Montagnani Francesca, Zanelli Giacomo, Borghetti Alberto, Dreassi Emanuela, Lombardi Francesca, Pecorari Monica, Borghi Vanni, Callegaro Annapaola, Micheli Valeria, Lodi Marco Annovazzi, Rossetti Barbara, Zazzi Maurizio

Abstract excerpt

OBJECTIVES: The aim of this study was to evaluate the impact of resistance mutations on efficacy of dolutegravir-based two-drug regimens (2DR). METHODS: Virologically suppressed patients with HIV-1 switching to dolutegravir + lamivudine or rilpivirine or to a dolutegravir-based three-drug regimen (3DR) with pre-baseline genotype were selected. Virological failure (VF) was defined as one HIV-RNA viral load (VL)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Heterocyclic Compounds, 3-Ring

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to Lamivudine

Share to Oxazines

Share to Piperazines

Share to Pyridones

Share to Rilpivirine

Source

Identifiers

PMID: 35092828
DOI: 10.1016/j.jgar.2022.01.018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study.PMID 35092828Read ↗

Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysisSemantic proximity Read ↗

HIV-1 drug resistance in people on dolutegravir-based ART: Collaborative analysis of cohort studiesSemantic proximity Read ↗

Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 InfectionSemantic proximity Read ↗

Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.Semantic proximity Read ↗

Virological Outcomes and Dolutegravir Resistance Mutations in HIV-infected Patients: A Multicenter Retrospective Cohort Study in MozambiqueSemantic proximity Read ↗

Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO).Semantic proximity Read ↗

A Comprehensive Literature Review of Treatment-Emergent Integrase Resistance with Dolutegravir-Based Regimens in Real-World Settings.Semantic proximity Read ↗

Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review.Semantic proximity Read ↗

Dolutegravir resistance mutations: lessons from monotherapy studies.Semantic proximity Read ↗

The Role of Prior HBV Infection and Resistance Mutations on the Efficacy of 3TC/DTG as a Maintenance TherapySemantic proximity Read ↗

Risk of Emergent Dolutegravir Resistance Mutations In People Living With HIV: A Rapid Scoping ReviewSemantic proximity Read ↗

Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.